Dasatinib, paclitaxel, and carboplatin in women with advanced-stage or recurrent endometrial cancer: A pilot clinical and translational study.

MLA

Coleman, Robert L., et al. “Dasatinib, Paclitaxel, and Carboplatin in Women with Advanced-Stage or Recurrent Endometrial Cancer: A Pilot Clinical and Translational Study.” Gynecologic Oncology, vol. 161, no. 1, Apr. 2021, pp. 104–12. EBSCOhost, https://doi.org/10.1016/j.ygyno.2021.01.022.

APA

Coleman, R. L., Hu, W., Soliman, P., Nick, A., Ramirez, P. T., Westin, S. N., Garcia, M. E., Zhu, Z., Palancia, J., Fellman, B. M., Yuan, Y., Ram, P., Bischoff, F., Schmeler, K., Bodurka, D., Meyer, L. A., & Sood, A. K. (2021). Dasatinib, paclitaxel, and carboplatin in women with advanced-stage or recurrent endometrial cancer: A pilot clinical and translational study. Gynecologic Oncology, 161(1), 104–112. https://doi.org/10.1016/j.ygyno.2021.01.022

Chicago

Coleman, Robert L, Wei Hu, Pamela Soliman, Alpa Nick, Pedro T Ramirez, Shannon N Westin, Michael E Garcia, et al. 2021. “Dasatinib, Paclitaxel, and Carboplatin in Women with Advanced-Stage or Recurrent Endometrial Cancer: A Pilot Clinical and Translational Study.” Gynecologic Oncology 161 (1): 104–12. doi:10.1016/j.ygyno.2021.01.022.